Wess Jürgen, Eglen Richard M, Gautam Dinesh
Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
Nat Rev Drug Discov. 2007 Sep;6(9):721-33. doi: 10.1038/nrd2379.
Muscarinic acetylcholine receptors (mAChRs), M(1)-M(5), regulate the activity of numerous fundamental central and peripheral functions. The lack of small-molecule ligands that can block or activate specific mAChR subtypes with high selectivity has remained a major obstacle in defining the roles of the individual receptor subtypes and in the development of novel muscarinic drugs. Recently, phenotypic analysis of mutant mouse strains deficient in each of the five mAChR subtypes has led to a wealth of new information regarding the physiological roles of the individual receptor subtypes. Importantly, these studies have identified specific mAChR-regulated pathways as potentially novel targets for the treatment of various important disorders including Alzheimer's disease, schizophrenia, pain, obesity and diabetes.
毒蕈碱型乙酰胆碱受体(mAChRs),即M(1)-M(5),调节众多基本的中枢和外周功能的活动。缺乏能够高选择性地阻断或激活特定mAChR亚型的小分子配体,仍然是确定各个受体亚型的作用以及开发新型毒蕈碱药物的主要障碍。最近,对缺乏五种mAChR亚型中每一种的突变小鼠品系进行的表型分析,已经产生了大量关于各个受体亚型生理作用的新信息。重要的是,这些研究已经确定特定的mAChR调节途径作为治疗包括阿尔茨海默病、精神分裂症、疼痛、肥胖症和糖尿病在内的各种重要疾病的潜在新靶点。